Loading…
Develops antibody-drug conjugates and biologics for cancer, discovered through a proprietary human antibody library.
Develops antibody-drug conjugates and biologics for cancer, discovered through a proprietary human antibody library.
Has no product on sale and funds its trials with money from investors; revenue so far has been small payments for research work done for others. Varegacestat, acquired from Ayala Pharmaceuticals, targets desmoid tumours, a rare soft-tissue growth with few treatments, so the main events are late-stage trial results and regulatory decisions.
Moat: none (IP / patents, data). Proprietary human antibody library aids target discovery but company is clinical-stage with no approved products.
Headquarters: Exton, Pennsylvania, US · Founded: 2005 · Employees: 177
Size Immunome (IMNM) is a United States Health Care company (Biotechnology) with a market value of $2.21B, the 1727th largest of 3,117 United States companies the cockpit tracks. Shares closed at $18.71 on 6 Nov 2026.
Performance Over six months the shares fell 16.6%, against +11.2% for the median peer and -1.1% for the United States market (cap-weighted) — 4th lowest of 21 in its peer set.
Growth Revenue fell 100.0% over the last twelve months (peer median +22.1%).
Next results Next results expected around 16 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $6.94M | $9.04M | $14.0M | $0 |
| Revenue growth | — | -23% | -36% | — | — |
| Gross profit | -$3.42M | $3.99M | $6.94M | $13.3M | -$631,000 |
| EBITDA | -$257M | -$211M | -$151M | -$109M | -$36.3M |
| Net income | -$254M | -$212M | -$293M | -$107M | -$36.9M |
| Free cash flow | -$219M | -$201M | -$118M | -$8.40M | -$28.9M |
| Capital expenditure | $10.3M | $9.69M | $7.17M | $831,000 | $248,000 |
| Total debt | $4.74M | $3.85M | $4.83M | $1.65M | $62,000 |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Immunome IMNM | $2.21B | -17% | -100% | n/a | n/a | n/a |
| Sutro Biopharma STRO | n/a | -76% | n/a | n/a | n/a | n/a |
| Daiichi Sankyo 4568.T | $31.9B | +7% | +17% | 13% | 2.1× | 7.2% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | IMNM | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -3.1% | +1.7% | 7th lowest of 21 |
| 6-month return | -16.6% | +11.2% | 4th lowest of 21 |
| Distance from 52-week high | -37.8% | -25.4% | 5th lowest of 21 |
| Revenue growth (TTM) | -100.0% | +22.1% | lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 0.3× | n/a | n/a |
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| Vir Biotechnology VIR | United States | $2.07B | +34% | +1,496% | -92% | 5.4× | n/a | n/a |
| Replimune REPL | United States | $2.05B | +547% | n/a | n/a | n/a | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 3.7× | n/a | n/a |
| Trevi Therapeutics TRVI | United States | $2.04B | -1% | n/a | n/a | n/a | n/a | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| First Tracks Biotherapeutics TRAX | United States | $2.01B | +145% | n/a | n/a | n/a | n/a | n/a |
| GemPharmatech 688046.SS | China | $2.01B | +59% | +25% | 22% | 13.3× | 35.7% | +24.8% |